Denysias Bioscience

Denysias Bioscience is a clinical-stage biotechnology company focused on developing precision medicines for neuropsychiatric disorders. The company was founded by industry veterans Jeff Jonas and Al Robichaud, who previously led Sage Therapeutics through significant growth and drug approvals. Denysias employs a precision medicine strategy, utilizing biomarkers and specific patient stratification to target CNS diseases more effectively than traditional broad-spectrum approaches. Its lead candidate, DS-101, is a brain-penetrant small molecule currently being evaluated in Phase 1 clinical trials for the treatment of schizophrenia. The company aims to address the high unmet need in psychiatry by focusing on specific biological drivers of disease. Denysias is headquartered in Cambridge, Massachusetts, and is backed by prominent investors such as ARCH Venture Partners and F-Prime Capital.